Gaspin

Asking for Preferences
Reading File
Finding Sources
Searching PubMed

gasping respiration causes clinical

Searching the Web

gasping breathing causes pathophysiology clinical significance

Reading File
Reading File
Searching Images

gasping agonal breathing respiratory pattern abnormal

This physiological data visualization displays respiratory monitoring results from a fiber-tip microcantilever breath sensor. Figure (A) illustrates a 100-second raw amplitude signal (blue waveform) representing time-dependent reflected light intensity. The signal exhibits periodic oscillations between approximately 0.6V and 1.4V, corresponding to real-time breathing cycles. Superimposed red circles indicate dynamic thresholds calculated from adjacent peak-valley pairs to account for baseline drift and turbulent airflow variations. Figure (B) displays a processed square-wave breath indicator derived from the dynamic thresholds in panel A. This binary signal alternates between state '0' (inhalation) and state '1' (exhalation), demonstrating a rhythmic, regular breathing pattern. The data illustrates the clinical application of micro-interferometer technology in respiratory rate (RR) monitoring and breath cycle phase identification, which is critical for assessing respiratory health and identifying abnormal ventilation patterns.

This physiological data visualization displays respiratory monitoring results from a fiber-tip microcantilever breath sensor. Figure (A) illustrates a 100-second raw amplitude signal (blue waveform) representing time-dependent reflected light intensity. The signal exhibits periodic oscillations between approximately 0.6V and 1.4V, corresponding to real-time breathing cycles. Superimposed red circles indicate dynamic thresholds calculated from adjacent peak-valley pairs to account for baseline drift and turbulent airflow variations. Figure (B) displays a processed square-wave breath indicator derived from the dynamic thresholds in panel A. This binary signal alternates between state '0' (inhalation) and state '1' (exhalation), demonstrating a rhythmic, regular breathing pattern. The data illustrates the clinical application of micro-interferometer technology in respiratory rate (RR) monitoring and breath cycle phase identification, which is critical for assessing respiratory health and identifying abnormal ventilation patterns.

This diagnostic image provides a comparison of human respiratory dynamics using sagittal-view gated CT imaging across three breathing patterns: normal, thoracic, and diaphragmatic. The panel is organized into two rows representing physiological states: 'End of expiration' (top) and 'End of inspiration' (bottom). Each column highlights a specific respiratory technique. In the bottom row (inspiration), a red outline superimposes the lung border from the previous expiratory phase to visually demonstrate lung volume expansion. Red arrows indicate primary mechanical drivers for each pattern: the thoracic breathing column displays anterior movement of the chest wall, while the diaphragmatic breathing column emphasizes significant inferior displacement of the diaphragm and expansion of the lower thoracic cavity. This comparison illustrates the mechanical differences between costal and abdominal breathing, demonstrating how different muscle groups contribute to changes in pleural pressure and lung volume. The imagery serves as an educational tool for pulmonology and physiology, focusing on respiratory mechanics and accessory muscle recruitment.

This diagnostic image provides a comparison of human respiratory dynamics using sagittal-view gated CT imaging across three breathing patterns: normal, thoracic, and diaphragmatic. The panel is organized into two rows representing physiological states: 'End of expiration' (top) and 'End of inspiration' (bottom). Each column highlights a specific respiratory technique. In the bottom row (inspiration), a red outline superimposes the lung border from the previous expiratory phase to visually demonstrate lung volume expansion. Red arrows indicate primary mechanical drivers for each pattern: the thoracic breathing column displays anterior movement of the chest wall, while the diaphragmatic breathing column emphasizes significant inferior displacement of the diaphragm and expansion of the lower thoracic cavity. This comparison illustrates the mechanical differences between costal and abdominal breathing, demonstrating how different muscle groups contribute to changes in pleural pressure and lung volume. The imagery serves as an educational tool for pulmonology and physiology, focusing on respiratory mechanics and accessory muscle recruitment.

Comparison chart showing physiologic waveforms across three cardiovascular states: (A) Normal sinus rhythm with spontaneous breathing, (B) Acute ventricular fibrillation (VF) with initial spontaneous breathing, and (C) Untreated VF with agonal gasping. The chart tracks three parameters over 15-second intervals: Aortic Pressure (AoP in mmHg), Air Flow (ml/s), and End-tidal CO2 (EtCO2 in mmHg). In state A, AoP shows regular rhythmic oscillations, and air flow exhibits a plateau in the inspiratory phase. In state B, AoP demonstrates a rapid decay in pulse pressure and mean arterial pressure following VF induction; air flow remains relatively regular but with slightly reduced amplitude and EtCO2 begins to decline. In state C, AoP is nearly flat, indicating a lack of cardiac output; the air flow signal transforms into sharp, infrequent 'gasping' peaks characterized by a lack of an inspiratory plateau and a rapid rise and fall, while the EtCO2 signal becomes irregular and significantly lower in amplitude. This infographic illustrates the hemodynamic and ventilatory changes during the progression of cardiac arrest.

Comparison chart showing physiologic waveforms across three cardiovascular states: (A) Normal sinus rhythm with spontaneous breathing, (B) Acute ventricular fibrillation (VF) with initial spontaneous breathing, and (C) Untreated VF with agonal gasping. The chart tracks three parameters over 15-second intervals: Aortic Pressure (AoP in mmHg), Air Flow (ml/s), and End-tidal CO2 (EtCO2 in mmHg). In state A, AoP shows regular rhythmic oscillations, and air flow exhibits a plateau in the inspiratory phase. In state B, AoP demonstrates a rapid decay in pulse pressure and mean arterial pressure following VF induction; air flow remains relatively regular but with slightly reduced amplitude and EtCO2 begins to decline. In state C, AoP is nearly flat, indicating a lack of cardiac output; the air flow signal transforms into sharp, infrequent 'gasping' peaks characterized by a lack of an inspiratory plateau and a rapid rise and fall, while the EtCO2 signal becomes irregular and significantly lower in amplitude. This infographic illustrates the hemodynamic and ventilatory changes during the progression of cardiac arrest.

Here is a thorough clinical overview of gasping (agonal respiration):

Gasping / Agonal Respiration

What Is It?

Gasping - also called agonal respiration - is an abnormal, involuntary pattern of breathing characterized by slow, labored, irregular breaths that may sound like snoring, snorting, choking, or moaning. It is driven by the lower brainstem (medulla oblongata) when higher brain centers fail, and it is not effective ventilation - it cannot sustain life on its own.
The physiology is well-established: when Lumsden transected the brain between the pons and medulla in animal experiments, breathing continued in an abnormal "gasping" pattern - confirming the medulla as the generator of last-resort respiratory drive. - Medical Physiology, p.1968

Contexts Where Gasping Occurs

1. Cardiac Arrest (most common)

Pulselessness combined with absent respiratory effort or only gasping/agonal respirations and unresponsiveness is diagnostic of cardiac arrest. - Goldman-Cecil Medicine, p.2100
Gasping occurs in approximately 40% of sudden cardiac arrests as the brainstem, deprived of oxygen, triggers involuntary reflex breaths. The waveform in cardiac arrest shows sharp, infrequent gasps with no inspiratory plateau - a stark contrast to normal breathing. The image below illustrates the hemodynamic and ventilatory shift from normal sinus rhythm to ventricular fibrillation to agonal gasping:
Agonal gasping waveform in cardiac arrest vs normal and VF states
Common underlying causes of cardiac arrest leading to gasping include:
  • Coronary artery disease / acute MI
  • Ventricular fibrillation or pulseless VT
  • Asystole / pulseless electrical activity
  • Hypertrophic cardiomyopathy (especially in young athletes)
  • Non-cardiac causes: massive PE, aortic rupture, subarachnoid hemorrhage - Goldman-Cecil Medicine, p.2095

2. Obstructive Sleep Apnea (OSA)

Choking or gasping episodes during sleep are a hallmark complaint reported by bed partners. In OSA, the upper airway collapses during sleep, causing apnea followed by arousal with a gasp. Associated features include snoring, witnessed apneas, morning headaches, and excessive daytime sleepiness. - Kaplan & Sadock's Synopsis of Psychiatry, p.643; Harriet Lane Handbook, p.5008

3. Severe Respiratory Distress (non-cardiac)

Profoundly dyspneic patients - e.g., those with COPD exacerbations - may display gasping respiration reflecting extreme air hunger. High-flow oxygen delivery systems are specifically indicated for such patients. - Morgan & Mikhail's Clinical Anesthesiology, p.3858
Opioids are actually used to suppress distressing gasping in end-stage COPD and palliative settings, where the air hunger triggers extreme agitation and panic. - Goodman & Gilman's Pharmacological Basis of Therapeutics, p.4917

Pathophysiology

FeatureDetail
GeneratorMedulla oblongata (brainstem)
TriggerHypoxia / anoxia / cerebral ischemia
NatureInvoluntary brainstem reflex, NOT effective breathing
DurationSeconds to minutes after cardiac arrest; longer in OSA arousals
SignificanceConfirms brainstem activity is present; does NOT mean the patient is breathing adequately

Key Clinical Points

  • Do not mistake agonal gasping for normal breathing - if a person is unresponsive and gasping, treat it as cardiac arrest and begin CPR immediately.
  • Gasping does not mean the patient is breathing adequately - it is a sign of cardiovascular/respiratory collapse.
  • In OSA, gasping is episodic and associated with arousal from sleep - it is not life-threatening in the same acute sense, but does impair sleep quality and carries long-term cardiovascular risk.
  • After cardiac arrest, gasping may persist for a few minutes after the heart stops due to brief residual brainstem perfusion.

Immediate Response

If you witness someone gasping and unresponsive:
  1. Call emergency services (911 / local emergency number)
  2. Begin CPR immediately - do not wait
  3. Use an AED if available
  4. Do not assume they are breathing adequately just because they are making sounds

Hocm

Reading File
Finding Sources
Searching PubMed

hypertrophic cardiomyopathy management

Searching Images

hypertrophic obstructive cardiomyopathy HOCM echocardiogram septal hypertrophy LVOT obstruction

This diagnostic image is a 2D color Doppler echocardiogram illustrating Hypertrophic Obstructive Cardiomyopathy (HOCM). The ultrasound shows significant asymmetrical septal hypertrophy, which leads to the narrowing of the Left Ventricular Outflow Tract (LVOT). The color Doppler overlay reveals complex, turbulent blood flow patterns: a prominent blue jet at the top indicating flow away from the transducer, and mosaic red-yellow regions in the mid-section suggestive of high-velocity flow and significant pressure gradients (96 mmHg). These findings are consistent with dynamic outflow obstruction and associated moderate-to-severe mitral regurgitation (MR). Additional visualized features include valvular and supravalvular pulmonary stenosis and a prominent eustachian valve. This clinical image is a primary educational resource for identifying the anatomical and hemodynamic markers of pediatric HOCM, specifically demonstrating the relationship between septal thickening and turbulent outflow.

This diagnostic image is a 2D color Doppler echocardiogram illustrating Hypertrophic Obstructive Cardiomyopathy (HOCM). The ultrasound shows significant asymmetrical septal hypertrophy, which leads to the narrowing of the Left Ventricular Outflow Tract (LVOT). The color Doppler overlay reveals complex, turbulent blood flow patterns: a prominent blue jet at the top indicating flow away from the transducer, and mosaic red-yellow regions in the mid-section suggestive of high-velocity flow and significant pressure gradients (96 mmHg). These findings are consistent with dynamic outflow obstruction and associated moderate-to-severe mitral regurgitation (MR). Additional visualized features include valvular and supravalvular pulmonary stenosis and a prominent eustachian valve. This clinical image is a primary educational resource for identifying the anatomical and hemodynamic markers of pediatric HOCM, specifically demonstrating the relationship between septal thickening and turbulent outflow.

This composite figure illustrates a case of Hypertrophic Obstructive Cardiomyopathy (HOCM) using multimodal imaging. Panel A shows a 2D transthoracic echocardiogram in the apical view, highlighting asymmetric septal hypertrophy (20mm thickness) and significant narrowing of the left ventricular outflow tract (LVOT). Two anomalous subvalvular chordae are visible attached to the interventricular septum and mitro-aortic trigone. Panel B is a Color Doppler image demonstrating turbulent, high-velocity flow acceleration (aliasing/mosaic pattern) across the LVOT and concomitant moderate mitral regurgitation. Panel C displays a Continuous-Wave (CW) Doppler tracing showing a peak velocity of 7.32 m/s and a peak pressure gradient of approximately 210 mmHg, characterized by a classic late-peaking 'dagger-shaped' waveform pathognomonic for dynamic LVOT obstruction. Panel D provides a cardiac MRI (CMR) correlation, confirming the abnormal insertion of chordae tendineae and the dominance of basal septal hypertrophy in causing the obstruction. This collection is used to teach the diagnostic features of dynamic outflow tract obstruction and the role of adjunctive imaging in characterizing subvalvular anatomy.

This composite figure illustrates a case of Hypertrophic Obstructive Cardiomyopathy (HOCM) using multimodal imaging. Panel A shows a 2D transthoracic echocardiogram in the apical view, highlighting asymmetric septal hypertrophy (20mm thickness) and significant narrowing of the left ventricular outflow tract (LVOT). Two anomalous subvalvular chordae are visible attached to the interventricular septum and mitro-aortic trigone. Panel B is a Color Doppler image demonstrating turbulent, high-velocity flow acceleration (aliasing/mosaic pattern) across the LVOT and concomitant moderate mitral regurgitation. Panel C displays a Continuous-Wave (CW) Doppler tracing showing a peak velocity of 7.32 m/s and a peak pressure gradient of approximately 210 mmHg, characterized by a classic late-peaking 'dagger-shaped' waveform pathognomonic for dynamic LVOT obstruction. Panel D provides a cardiac MRI (CMR) correlation, confirming the abnormal insertion of chordae tendineae and the dominance of basal septal hypertrophy in causing the obstruction. This collection is used to teach the diagnostic features of dynamic outflow tract obstruction and the role of adjunctive imaging in characterizing subvalvular anatomy.

This diagnostic image is a 2D transthoracic echocardiogram in a parasternal long-axis (PLAX) orientation, illustrating hallmark features of Hypertrophic Obstructive Cardiomyopathy (HOCM). The ultrasound shows significant asymmetrical septal hypertrophy, where the interventricular septum (IVS) is markedly thickened compared to the posterior wall of the left ventricle. This septal bulging narrows the left ventricular outflow tract (LVOT), creating a substrate for dynamic obstruction. The image also captures the relationship between the hypertrophied septum and the anterior leaflet of the mitral valve, which often exhibits systolic anterior motion (SAM) in such clinical presentations. The increased echogenicity of the myocardial tissue in the septal region suggests densification or fibrosis consistent with cardiomyocyte disarray. This imaging modality is essential for evaluating cardiac structural abnormalities, assessing blood flow velocities, and measuring peak gradients across the LVOT to determine the severity of obstructive cardiac conditions in pediatric or adult cardiology.

This diagnostic image is a 2D transthoracic echocardiogram in a parasternal long-axis (PLAX) orientation, illustrating hallmark features of Hypertrophic Obstructive Cardiomyopathy (HOCM). The ultrasound shows significant asymmetrical septal hypertrophy, where the interventricular septum (IVS) is markedly thickened compared to the posterior wall of the left ventricle. This septal bulging narrows the left ventricular outflow tract (LVOT), creating a substrate for dynamic obstruction. The image also captures the relationship between the hypertrophied septum and the anterior leaflet of the mitral valve, which often exhibits systolic anterior motion (SAM) in such clinical presentations. The increased echogenicity of the myocardial tissue in the septal region suggests densification or fibrosis consistent with cardiomyocyte disarray. This imaging modality is essential for evaluating cardiac structural abnormalities, assessing blood flow velocities, and measuring peak gradients across the LVOT to determine the severity of obstructive cardiac conditions in pediatric or adult cardiology.

This diagnostic image displays a dual-panel transthoracic echocardiogram (TTE) in a parasternal long-axis view, illustrating key pathological hallmarks of Hypertrophic Obstructive Cardiomyopathy (HOCM). Panel A demonstrates significant asymmetric septal hypertrophy, with the interventricular septum (IVS) measured at 27 mm. The hypertrophied myocardium exhibits a dense, speckled echogenicity pattern. Panel B identifies the hemodynamic consequence of this structural change: systolic anterior motion (SAM) of the anterior mitral valve leaflet. White arrows highlight the abnormal anterior displacement of the mitral leaflet toward the hypertrophied septum during systole, a mechanism that contributes to left ventricular outflow tract (LVOT) obstruction. These findings are critical for diagnosing obstructive phenotypes of hypertrophic cardiomyopathy and assessing the risk of dynamic outflow obstruction.

This diagnostic image displays a dual-panel transthoracic echocardiogram (TTE) in a parasternal long-axis view, illustrating key pathological hallmarks of Hypertrophic Obstructive Cardiomyopathy (HOCM). Panel A demonstrates significant asymmetric septal hypertrophy, with the interventricular septum (IVS) measured at 27 mm. The hypertrophied myocardium exhibits a dense, speckled echogenicity pattern. Panel B identifies the hemodynamic consequence of this structural change: systolic anterior motion (SAM) of the anterior mitral valve leaflet. White arrows highlight the abnormal anterior displacement of the mitral leaflet toward the hypertrophied septum during systole, a mechanism that contributes to left ventricular outflow tract (LVOT) obstruction. These findings are critical for diagnosing obstructive phenotypes of hypertrophic cardiomyopathy and assessing the risk of dynamic outflow obstruction.

Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Reading File
Reading File
Searching the Web

HOCM 2024 AHA ACC guideline treatment mavacamten septal reduction

Here is a comprehensive overview of HOCM:

HOCM - Hypertrophic Obstructive Cardiomyopathy

Definition

HCM is defined as unexplained left ventricular hypertrophy in the absence of abnormal loading conditions (valve disease, hypertension, congenital heart defects) sufficient to explain the degree of hypertrophy. Prevalence: 0.2-0.5% worldwide, affecting all racial groups. The obstructive subtype (HOCM) involves dynamic LVOT obstruction at rest or with provocation. - Goldman-Cecil Medicine, p.4459

Genetics & Pathogenesis

  • Autosomal dominant inheritance with variable penetrance
  • Mutations in sarcomeric contractile protein genes account for ~50-60% of cases; >1400 mutations identified
  • Key genes: MYH7 (β-myosin heavy chain), MYBPC3 (myosin-binding protein C), TNNT2 (troponin T) - these three account for 70-80% of all HCM cases
  • Mutations are gain-of-function → myocyte hypercontractility → increased energy use → net negative energy balance - Robbins & Kumar Basic Pathology, p.1125
  • The same genes mutated in DCM cause loss-of-function, while in HCM they cause gain-of-function - an important distinction

Morphology / Pathology

Gross:
  • Massive myocardial hypertrophy without ventricular dilation
  • 90% asymmetric septal hypertrophy (IVS >> LV free wall); 10% concentric
  • LV cavity compressed into a "banana-shaped" configuration
  • Anterior mitral leaflet contacts the hypertrophied septum during systole → fibrous endocardial plaque in LVOT
  • Left atrium is enlarged
HOCM gross and histology - asymmetric septal hypertrophy with banana-shaped LV cavity and fibrous endocardial plaque (arrow), plus myocyte disarray on histology
Histology (3 hallmarks):
  1. Myocyte hypertrophy (extreme)
  2. Myocyte/myofiber disarray (haphazard arrangement)
  3. Interstitial fibrosis
  • Robbins & Kumar Basic Pathology, p.1143

Mechanism of LVOT Obstruction

The obstruction in HOCM is dynamic (worsens with reduced preload or increased contractility), not fixed. Two components work together:
  1. Asymmetric septal hypertrophy narrows the LVOT anatomically
  2. Systolic Anterior Motion (SAM) of the mitral valve - the anterior mitral leaflet is dragged toward the hypertrophied septum during ejection by the Venturi effect, further obstructing the LVOT and causing mitral regurgitation
The classic echocardiographic finding is a "dagger-shaped" late-peaking CW Doppler waveform across the LVOT:
HOCM echocardiogram showing asymmetric septal hypertrophy 20mm, SAM of mitral valve, turbulent LVOT flow, and dagger-shaped CW Doppler with peak gradient 210 mmHg
HOCM parasternal long-axis echo showing IVS 27mm and SAM of anterior mitral leaflet (white arrows)

Clinical Features

Typically manifests during or after puberty. Symptoms reflect:
  • Diastolic dysfunction (impaired relaxation → reduced filling)
  • LVOT obstruction (reduced cardiac output)
  • Secondary pulmonary venous hypertension
FeatureDetail
Exertional dyspneaMost common symptom
AnginaMyocardial ischemia despite normal coronaries (massive hypertrophy + impaired intramural flow)
Syncope / presyncopeFrom LVOT obstruction or arrhythmia
Harsh systolic ejection murmurIncreases with Valsalva/standing (↓preload worsens obstruction); decreases with squatting (↑preload)
Atrial fibrillationRisk of mural thrombus and stroke
Sudden cardiac deathVentricular fibrillation - leading cause in athletes <35 years
CHFLate complication
  • Robbins & Kumar Basic Pathology, p.1145; Goldman-Cecil Medicine, p.4197

Echocardiographic Diagnosis

Echo is the cornerstone of diagnosis. Key findings:
  • Asymmetric septal hypertrophy (IVS ≥15 mm, or ratio IVS:posterior wall >1.3)
  • Systolic Anterior Motion (SAM) of mitral valve
  • Dynamic LVOT obstruction (peak gradient ≥30 mmHg at rest, ≥50 mmHg provoked = hemodynamically significant)
  • Diastolic dysfunction
  • Mitral regurgitation (secondary to SAM)
  • Textbook of Clinical Echocardiography, p.3380-3388
TEE is used intraprocedurally during septal myectomy to guide the depth, width, and length of resection and assess residual obstruction. - Textbook of Clinical Echocardiography, p.3380

Management (2024 AHA/ACC Guideline)

The 2024 AHA/ACC/Multisociety Guideline (PMID: 38718139) is the current reference.

Stepwise Pharmacological Approach for Obstructive HCM

Step 1 - First-line (Class 1):
  • Beta-blockers OR non-dihydropyridine CCBs (verapamil, diltiazem)
  • Add oral diuretic if congestion present (Class 2a)
Step 2 - Persistent symptoms:
  • Add mavacamten (cardiac myosin ATPase inhibitor) - Class 2a
    • OR add disopyramide
    • OR refer for septal reduction therapy (Class 1, at experienced centers)
Key drug - Mavacamten: The first FDA-approved cardiac myosin inhibitor. It inhibits actin-myosin interaction, reducing contractility and LVOT obstruction. In the Phase 3 VALOR-HCM trial, 82% of patients on mavacamten no longer met criteria for septal reduction therapy at 16 weeks vs. 23% on placebo. Requires echocardiographic surveillance of LVEF during titration.
Drugs to AVOID in obstructive HCM:
  • Vasodilators (nitrates, dihydropyridine CCBs)
  • Digoxin
  • High-dose diuretics (reduce preload → worsen obstruction)

Septal Reduction Therapy (SRT)

Two options, both Class 1 at experienced centers:
ProcedureDescriptionPreferred When
Surgical myectomyTransaortic resection of basal septumAnomalous papillary muscle, elongated mitral leaflet, intrinsic MV disease, multivessel CAD, valvular AS
Alcohol septal ablationEthanol injected into septal perforator → controlled infarction of proximal septumOlder patients, high surgical risk
Mitral valve replacement should NOT be performed for the sole purpose of relieving LVOTO (Class 3: Harm). SRT should NOT be performed in asymptomatic patients with normal exercise capacity (Class 3: Harm).

ICD / SCD Prevention

  • ICD implantation considered for patients with high SCD risk (prior cardiac arrest, sustained VT, massive hypertrophy ≥30mm, family history of SCD, unexplained syncope, NSVT on Holter, abnormal BP response to exercise)
  • Quantitative late gadolinium enhancement on cardiac MRI is a powerful predictor of SCD risk - meta-analysis 2024 (PMID: 37632503)

Atrial Fibrillation in HCM

  • Preferred rate/rhythm control: disopyramide + beta-blocker, verapamil, diltiazem, or amiodarone
  • All patients with HCM and AF should receive anticoagulation (high thromboembolic risk)

Key Differentials

ConditionDistinguishing Features
Hypertensive LVHConcentric, symmetric; responds to BP treatment
Aortic stenosisFixed LVOT obstruction; murmur decreases with Valsalva
Athletic heartRegression with detraining; no SAM; normal diastolic function
Cardiac amyloidRestrictive pattern; sparkling echo texture; low-voltage ECG

Bottom line: HOCM is a genetically driven, autosomal dominant cardiomyopathy with asymmetric septal hypertrophy, dynamic LVOT obstruction via SAM, diastolic dysfunction, and preserved systolic function. It is the #1 cause of sudden death in young athletes. Management has evolved significantly with mavacamten offering a novel pharmacological alternative to invasive septal reduction.

Fibroid

Reading File
Finding Sources
Searching Images

uterine fibroid leiomyoma types submucosal intramural subserosal diagram

A gray-scale transvaginal ultrasound image in a longitudinal view demonstrating a uterine fibroid (leiomyoma) located in the posterior wall of the uterine fundus. The lesion is characterized as a solid, well-defined, and predominantly hypoechoic mass relative to the adjacent myometrium. Its internal echotexture is heterogeneous with visible areas of varying gray-scale intensity. According to the FIGO classification system, this is a FIGO Type 6 fibroid, defined as a subserosal lesion with an intramural component involving less than 50% of its volume. The image clearly shows the majority of the fibroid protruding from the uterine serosa into the pelvic space, while a smaller portion remains embedded within the muscular uterine wall. This diagnostic image is essential for gynecological assessment and surgical planning, helping to differentiate between intramural, submucosal, and subserosal pathologies.

A gray-scale transvaginal ultrasound image in a longitudinal view demonstrating a uterine fibroid (leiomyoma) located in the posterior wall of the uterine fundus. The lesion is characterized as a solid, well-defined, and predominantly hypoechoic mass relative to the adjacent myometrium. Its internal echotexture is heterogeneous with visible areas of varying gray-scale intensity. According to the FIGO classification system, this is a FIGO Type 6 fibroid, defined as a subserosal lesion with an intramural component involving less than 50% of its volume. The image clearly shows the majority of the fibroid protruding from the uterine serosa into the pelvic space, while a smaller portion remains embedded within the muscular uterine wall. This diagnostic image is essential for gynecological assessment and surgical planning, helping to differentiate between intramural, submucosal, and subserosal pathologies.

A pathophysiology diagram illustrating the genetic and epigenetic factors involved in the pathogenesis of uterine leiomyoma (fibroids). The central visual element is an anatomical illustration of a uterus with multiple intramural and subserosal leiomyomas, labeled 'Uterine Leiomyoma.' Surrounding this central figure are five color-coded categorical boxes with arrows pointing toward the uterus, indicating their contributory roles. The categories and specific genes/factors listed include: 1) Inflammatory Genes (Interleukins, TNF Alpha); 2) Transcription Factor Genes (MED12, HMGA); 3) Growth Factor Genes (VEGF, IGF, TGF Beta, Cytochrome P450); 4) DNA Repair Genes (TP53, P21, XRCC1, VDR); and 5) Hormonal Receptor Genes (Estrogen, Progesterone). Each category box is accompanied by a small icon representing biological structures like DNA strands or receptors. This educational diagram is intended for oncology and gynecology curricula to summarize the polygenic nature of fibroid development and susceptibility.

A pathophysiology diagram illustrating the genetic and epigenetic factors involved in the pathogenesis of uterine leiomyoma (fibroids). The central visual element is an anatomical illustration of a uterus with multiple intramural and subserosal leiomyomas, labeled 'Uterine Leiomyoma.' Surrounding this central figure are five color-coded categorical boxes with arrows pointing toward the uterus, indicating their contributory roles. The categories and specific genes/factors listed include: 1) Inflammatory Genes (Interleukins, TNF Alpha); 2) Transcription Factor Genes (MED12, HMGA); 3) Growth Factor Genes (VEGF, IGF, TGF Beta, Cytochrome P450); 4) DNA Repair Genes (TP53, P21, XRCC1, VDR); and 5) Hormonal Receptor Genes (Estrogen, Progesterone). Each category box is accompanied by a small icon representing biological structures like DNA strands or receptors. This educational diagram is intended for oncology and gynecology curricula to summarize the polygenic nature of fibroid development and susceptibility.

This clinical photograph captures an intraoperative view of an exteriorized uterus during a cesarean section. The primary finding is a large, well-circumscribed, subserosal uterine leiomyoma (fibroid), approximately 9 cm in size, located on the left anterior lateral uterine wall (indicated by a white arrow). The fibroid presents as a smooth, reddish-pink bulbous mass protruding from the uterine serosa. To the lower left of the primary uterine body (anatomical right), a normal right fallopian tube (marked with an asterisk) and right ovary (marked with an 'x') are clearly visualized. The uterine tissue appears hyperemic, typical of the gravid state. The surgical field includes sterile drapes, gloved hands of the surgeon, and a surgical retractor. This image serves as a significant clinical example of a large subserosal fibroid encountered during obstetric surgery and illustrates the anatomical relationships between the gravid uterus, adnexa, and intramural pathology.

This clinical photograph captures an intraoperative view of an exteriorized uterus during a cesarean section. The primary finding is a large, well-circumscribed, subserosal uterine leiomyoma (fibroid), approximately 9 cm in size, located on the left anterior lateral uterine wall (indicated by a white arrow). The fibroid presents as a smooth, reddish-pink bulbous mass protruding from the uterine serosa. To the lower left of the primary uterine body (anatomical right), a normal right fallopian tube (marked with an asterisk) and right ovary (marked with an 'x') are clearly visualized. The uterine tissue appears hyperemic, typical of the gravid state. The surgical field includes sterile drapes, gloved hands of the surgeon, and a surgical retractor. This image serves as a significant clinical example of a large subserosal fibroid encountered during obstetric surgery and illustrates the anatomical relationships between the gravid uterus, adnexa, and intramural pathology.

This diagnostic ultrasound image demonstrates the FIGO (International Federation of Gynecology and Obstetrics) classification system for uterine fibroids (leiomyomas). The image shows a grayscale sagittal view of a uterus with heterogeneous, hypoechoic texture. Numbered circular overlays are used to map fibroid locations relative to the uterine wall layers. Red markers 0, 1, and 2 identify 'Submucosal' fibroids (ranging from pedunculated intracavitary to ≥ 50% intramural). Green markers 3 and 4 identify 'Intramural' fibroids. Blue markers 5, 6, and 7 represent 'Subserosal' positions (ranging from ≥ 50% intramural to pedunculated subserosal). A large purple oval labeled '2-5' indicates the 'Hybrid Type' (contacting both the endometrium and serosa, but < 50% of each), and a gray marker '8' indicates 'Other' locations such as cervical or parasitic fibroids. This anatomical diagram serves as an educational guide for clinicians to determine surgical approaches, such as hysteroscopic versus laparoscopic myomectomy, based on lesion classification.

This diagnostic ultrasound image demonstrates the FIGO (International Federation of Gynecology and Obstetrics) classification system for uterine fibroids (leiomyomas). The image shows a grayscale sagittal view of a uterus with heterogeneous, hypoechoic texture. Numbered circular overlays are used to map fibroid locations relative to the uterine wall layers. Red markers 0, 1, and 2 identify 'Submucosal' fibroids (ranging from pedunculated intracavitary to ≥ 50% intramural). Green markers 3 and 4 identify 'Intramural' fibroids. Blue markers 5, 6, and 7 represent 'Subserosal' positions (ranging from ≥ 50% intramural to pedunculated subserosal). A large purple oval labeled '2-5' indicates the 'Hybrid Type' (contacting both the endometrium and serosa, but < 50% of each), and a gray marker '8' indicates 'Other' locations such as cervical or parasitic fibroids. This anatomical diagram serves as an educational guide for clinicians to determine surgical approaches, such as hysteroscopic versus laparoscopic myomectomy, based on lesion classification.

Searching PubMed

uterine fibroids leiomyoma management

Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Searching the Web

uterine fibroids FIGO classification medical treatment relugolix elagolix 2024 2025

Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Loading Image
Here is a thorough clinical overview of uterine fibroids:

Uterine Fibroids (Leiomyoma / Myoma)

Definition

A uterine myoma (fibroid, leiomyoma) is a benign monoclonal smooth muscle tumor originating from the myometrial layer of the uterus. It is the most common pelvic tumor in women, present in up to 40% of women during reproductive years and up to 70-80% by age 50. - Goldman-Cecil Medicine, p.465

Genetics & Pathogenesis

  • Fibroids are estrogen- and progesterone-dependent - they grow during reproductive years and shrink after menopause
  • Most grow slowly; in pregnancy they may rapidly enlarge early but typically do not grow further
  • Key mutations:
    • MED12 gene (X chromosome) - most common somatic mutation
    • FH (fumarate hydratase) gene germline mutations - associated with early-onset uterine + cutaneous leiomyomas + renal cell carcinoma (Reed's syndrome)
  • Also involve: inflammatory genes (interleukins, TNF-alpha), growth factor genes (VEGF, TGF-beta, IGF), hormonal receptor genes (estrogen, progesterone)
  • Robbins Pathology, p.221; Goldman-Cecil Medicine, p.465

FIGO Classification by Location

This is the standard classification for surgical and therapeutic planning:
FIGO classification of uterine fibroids on ultrasound - submucosal (0-2), intramural (3-4), subserosal (5-7), hybrid (2-5), and other (8)
FIGO TypeLocationClinical Significance
0Pedunculated intracavitaryWorst bleeding; hysteroscopic removal
1Submucosal, <50% intramuralHeavy menstrual bleeding, subfertility
2Submucosal, ≥50% intramuralHeavy menstrual bleeding
3Intramural, touches endometriumBleeding + fertility impact
4IntramuralBulk symptoms, variable bleeding
5Subserosal, ≥50% intramuralBulk/pressure symptoms
6Subserosal, <50% intramuralBulk/pressure symptoms
7Pedunculated subserosalTorsion risk; least effect on bleeding
8Other (cervical, parasitic)Variable
2-5Hybrid (transmural)Both bleeding and bulk

Clinical Features

Most fibroids are asymptomatic (found incidentally on imaging). When symptomatic:
SymptomNotes
Heavy menstrual bleeding (HMB)Most common; caused especially by submucosal fibroids distorting the endometrial cavity
Pelvic pain / pressure / fullnessBulk symptoms from large/multiple fibroids
DysmenorrhoeaPainful periods
Subfertility / recurrent miscarriageSubmucosal fibroids most implicated
Urinary frequency / urgencyBladder compression by anterior fibroids
ConstipationPosterior fibroids pressing on rectum
Acute painFrom fibroid degeneration (especially in pregnancy) or torsion of pedunculated fibroid
  • Goldman-Cecil Medicine, p.467; Creasy & Resnik Maternal-Fetal Medicine, p.3062
Important: Fibroids are benign and not premalignant. However, ~1 in 1,100-1,500 women under 45 with a suspected fibroid may harbor uterine sarcoma - this possibility must always be considered. - Goldman-Cecil Medicine, p.469

Diagnosis

  • Pelvic examination: enlarged, irregularly shaped, non-tender uterus
  • Transvaginal ultrasound (TVS): first-line imaging - spherical, well-defined, hypoechoic mass; heterogeneous if degenerated
  • MRI: gold standard for fibroid mapping pre-surgery; best defines size, number, and location
  • Sonohysterography / hysteroscopy: best for submucosal fibroids
  • PALM-COEIN classification is used for abnormal uterine bleeding; "L" = leiomyoma
On ultrasound, fibroids appear as hypoechoic masses; degeneration causes heterogeneous internal echoes and possible liquefaction. - Creasy & Resnik, p.3058-3064
Subserosal fibroid on transvaginal ultrasound - well-defined hypoechoic posterior fundal mass, FIGO Type 6

Management

When to Treat?

Treat only if symptomatic (bleeding, pain, bulk, subfertility). Asymptomatic fibroids require no intervention.

Medical (Non-surgical) Options

AgentMechanismNotes
NSAIDs (naproxen, mefenamic acid)Prostaglandin inhibitionReduces pain and bleeding; first-line for mild symptoms
Combined OCP / LNG-IUSHormonal suppressionReduce bleeding but do not shrink fibroids
GnRH agonists (leuprolide)Suppresses estrogenShrinks fibroids 30-50%; used pre-op; menopausal SE, max 6 months
Oral GnRH antagonistsImmediate estrogen suppressionElagolix 300mg BD + add-back, or Relugolix 40mg OD + estradiol 1mg + norethindrone 0.5mg (Myfembree) - FDA-approved; reduces HMB and preserves bone density; up to 2 years use
Mifepristone (5-10mg)Anti-progesteroneEffective 6-month course
Ulipristal acetateSelective progesterone receptor modulator5-10mg for 13 weeks; EU use suspended due to liver toxicity concerns
The FIGO best practice guidance 2025 (PMID: 40927887) and SOGC Guideline No. 461 (2025) (PMID: 40562356) are the most current management references.

Surgical / Procedural Options

ProcedureDescriptionBest For
Hysteroscopic myomectomyEndoscopic removal via the cervixSubmucosal (FIGO 0-2); preserves fertility
Laparoscopic myomectomyKeyhole surgeryIntramural/subserosal; fertility-preserving
Open (abdominal) myomectomyLarge or multiple fibroidsFertility-preserving; highest recurrence risk
Uterine artery embolization (UAE)Cuts blood supply to fibroidsSuitable for women not wanting surgery; 28% need subsequent hysterectomy
Radiofrequency ablationThermal destructionNewer; outpatient; non-fertility-preserving data limited
MRI-guided focused ultrasoundNon-invasive thermal ablationSuitable selected patients
HysterectomyDefinitive cureNo desire for future pregnancy; recurrence impossible
Important note: Myomectomy provides better outcomes than UAE for most symptomatic presentations. - Goldman-Cecil Medicine, p.486; meta-analysis 2024, PMID 39164326
Power morcellation has fallen out of favor due to the risk of disseminating occult uterine sarcoma. - Goldman-Cecil Medicine, p.486

Fibroid Recurrence After Myomectomy

  • Cumulative risk of clinically significant new fibroids: ~10% at 5 years (sonographic detection higher: ~51% at 5 years if no size limit used)
  • Risk of requiring a second surgery: 11% if single fibroid removed, 26% if multiple
  • Subsequent childbearing is protective: 10-year recurrence 16% vs. 28% without pregnancy
  • Berek & Novak's Gynecology, p.204-237

Fibroids in Pregnancy

  • Detected in ~3-4% of midtrimester ultrasound scans
  • Associated with: placenta previa (OR 2.2), preterm birth, malpresentation
  • Degeneration can cause acute pain in pregnancy (treated conservatively with analgesia)
  • Myomectomy during cesarean section is generally avoided unless absolutely necessary
  • Creasy & Resnik Maternal-Fetal Medicine, p.3064

Key Summary

  • Most fibroids are asymptomatic - only treat if symptomatic
  • Submucosal fibroids cause the most bleeding and fertility problems
  • Relugolix (Myfembree) and elagolix (Oriahnn) are modern oral GnRH antagonists with add-back that are now standard of care for medical management
  • Myomectomy preserves fertility; hysterectomy is the only definitive cure
  • Always exclude uterine sarcoma before assuming a rapidly enlarging mass is benign
This is a shared conversation. Sign in to Orris to start your own chat.